“We’re delighted to have delivered our first quarterly Adjusted EBITDA profit as a public company,” said Clover Health CEO Andrew Toy. “We have been strategically focused on demonstrating the strength of our model by maturing operations, driving efficiencies, and continuing to invest in Clover Assistant R&D and our home care capabilities. We have multiple exciting initiatives in each of these areas that we expect will allow us to maintain our momentum through the second half of the year and into 2024. We are reflecting that expectation via significantly improved full year 2023 guidance for the Insurance segment and on a consolidated basis.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CLOV:
- Clover Health Reports Strong Second Quarter 2023 Results; Highlights Improved Financial Performance and Guidance Ranges
- Clover Health options imply 16.3% move in share price post-earnings
- Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement
- Clover Health to Present at Canaccord Genuity 43rd Annual Growth Conference and 2023 Wells Fargo Healthcare Conference
- Clinician Use of Clover Assistant is Associated with Significant Improvement in the Early Identification and Management of Chronic Kidney Disease
